Biome Australia Limited Appendix 4E Preliminary final report

1. Company details

Name of entity:	Biome Australia Limited
ABN:	51 627 364 014
Reporting period:	For the year ended 30 June 2023
Previous period:	For the year ended 30 June 2022

2. Results for announcement to the market

			\$
Revenues from ordinary activities	up	75.5% to	7,235,611
Loss from ordinary activities after tax attributable to the owners of Biome Australia Limited	down	32.2% to	(3,078,527)
Loss for the year attributable to the owners of Biome Australia Limited	down	32.2% to	(3,078,527)

Dividends

There were no dividends paid, recommended or declared during the current financial period.

Comments

The Company recorded revenue of \$7,235,611 for the year, an increase of 75.5% compared to previous corresponding period (FY22). The loss for the consolidated entity after providing for income tax decreased by 32.2% and amounted to \$3,078,527 (30 June 2021: \$4,540,580).

Financial Performance

The Company continued to experience strong sales growth during the year with revenue increasing by 75.5% to \$7,235,611 compared to the previous corresponding period (FY22 \$4,122,425). The strong sales growth has been driven by Biome's Activated Probiotics, range of live biotherapeutics (probiotics).

Following a successful launch into Wesfarmers-owned, Wesfarmers Health and Priceline Pharmacy, Activated Probiotics became the fastest-growing brand in the professional vitamin category across Priceline Pharmacy stores. Activated Probiotics also continues to be the number one growth brand in Terry White Chemmart, Australia's largest pharmacy group, and with the national pharmacy distributors, API and Symbion. Biome recorded strong growth in community pharmacy sales with a 27% increase in same-store-sales between Q3 and Q4 FY23. At the close of FY23, Biome's Activated Probiotics was available through more than 4000 distribution points nationally with a gross margin of 59%. Practitioner channel sales continue to grow and accounted for 35% of total sales revenue for the year, growing by over 90% compared to the previous corresponding period.

Sales and marketing costs increased by \$1,327,837 to \$4,930,498 because of increased expenditure on promoting the Company's products. Total operating expenses for the year increased by \$545,390 or 7.58% to \$7,743,800 against a revenue increase of 75.5%. The result was a loss for the consolidated entity after providing for income tax of \$3,078,527, a reduction of 32.2% from FY22 (30 June 2022: \$4,540,580).

Financial Position

The Company has \$2,260,764 in cash as at 30 June 2023 and a further \$700,000 in undrawn credit facility.

The net assets of the Company decreased by \$2,938,782 from June 2022 to \$3,586,265 as at 30 June 2023 which was a result of funding the Company's operations for the year.

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	1.78	3.26

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period There were no dividends paid, recommended or declared during the current financial period.

Previous period

There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

8. Details of associates and joint venture entities

Not applicable.

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

This report is in the process of being audited. At the date of this report, the Directors are not aware of any matter that will result in a qualification of the audit report.

11. Attachments

Details of attachments (if any):

Preliminary Financial Report for the year ended 30 June 2023

Biome Australia Limited Statement of profit or loss and other comprehensive income For the year ended 30 June 2023

	Note	Consoli 30 June 2023 3 \$	
Revenue Sales revenue Cost of goods sold	5	7,235,611 (2,960,083)	4,122,425 (1,735,252)
Gross profit		4,275,528	2,387,173
Other income	6	389,745	270,657
Expenses Sales and marketing expenses Corporate and administrative expenses Occupancy expenses Depreciation, amortisation and impairments Other expenses Finance costs Loss before income tax expense Income tax expense Loss after income tax expense for the year attributable to the owners of Biome	7 7 7 7 8	(4,930,498) (2,244,947) (157,568) (220,377) (76,513) (113,897) (3,078,527)	(3,602,661) (2,792,646) (205,538) (83,589) (466,619) (47,357) (4,540,580)
Australia Limited	24	(3,078,527)	(4,540,580)
Other comprehensive income for the year, net of tax		<u> </u>	
Total comprehensive income for the year attributable to the owners of Biome Australia Limited		(3,078,527)	(4,540,580)
		Cents	Cents
Basic earnings per share Diluted earnings per share	32 32	(1.53) (1.53)	(2.57) (2.57)

Biome Australia Limited Statement of financial position As at 30 June 2023

	Note	Consolidated 30 June 2023 30 June 202 \$ \$	
Assets			
Current assets Cash and cash equivalents Trade and other receivables Inventories Other Total current assets	9 10 11 12	2,260,764 1,443,044 3,021,314 45,902 6,771,024	5,493,394 794,148 1,300,075 55,939 7,643,556
Non-current assets Property, plant and equipment Right-of-use assets Total non-current assets	13 14	453,295 334,963 788,258	174,695 433,000 607,695
Total assets		7,559,282	8,251,251
Liabilities			
Current liabilities Trade and other payables Borrowings Lease liabilities Employee benefits Total current liabilities	15 16 17 18	2,274,371 125,018 99,584 487,413 2,986,386	1,125,558 - 91,700 <u>133,598</u> 1,350,856
Non-current liabilities Borrowings Lease liabilities Employee benefits Total non-current liabilities	19 20 21	645,240 275,765 <u>65,626</u> 986,631	- 375,348 - 375,348
Total liabilities		3,973,017	1,726,204
Net assets		3,586,265	6,525,047
Equity Issued capital Reserves Accumulated losses Total equity	22 23 24	20,764,055 421,257 (17,599,047) 3,586,265	20,639,835 415,442 (14,530,230) 6,525,047
i otal oquity		0,000,200	0,020,047

Biome Australia Limited Statement of changes in equity For the year ended 30 June 2023

Consolidated	lssued capital \$	Option Reserves \$	Performance rights \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2021	9,830,488	83,205	1,559,970	(9,893,535)	1,580,128
Loss after income tax expense for the year Other comprehensive income for the year, net of tax	-	-	-	(4,540,580)	(4,540,580)
Total comprehensive income for the year	-	-	-	(4,540,580)	(4,540,580)
<i>Transactions with owners in their capacity as owners:</i> Contributions of equity, net of transaction costs					
(note 22) Share-based payments (note 33)	8,508,210 -	- 405,734	-	-	8,508,210 405,734
Exercise of performance rights Cancellation of options Issue of performance rights	2,301,137 - -	- (73,497) -	585,615	- 59,437 -	- (14,060) 585,615
Transfer to accumulated losses	<u> </u>	<u> </u>	155,552	(155,552)	-
Balance at 30 June 2022	20,639,835	415,442		(14,530,230)	6,525,047
Consolidated	lssued capital \$	Option Reserves \$	Performance rights \$	Accumulated losses \$	Total equity \$
Balance at 1 July 2022	20,639,835	415,442	-	(14,530,230)	6,525,047
Loss after income tax expense for the year Other comprehensive income for the year, net of tax	-	-	-	(3,078,527)	(3,078,527)
Total comprehensive income for the year	-	-	-	(3,078,527)	(3,078,527)
<i>Transactions with owners in their capacity as owners:</i> Contributions of equity, net of transaction costs					
(note 22) Share-based payments (note 33) Cancellation of options	124,220 - -	- 15,525 (9,710)	- - -	- - 9,710	124,220 15,525 -
Balance at 30 June 2023	20,764,055	421,257		(17,599,047)	3,586,265

Biome Australia Limited Statement of cash flows For the year ended 30 June 2023

	Note	Consol 30 June 2023 \$	
Cash flows from operating activities		Ŧ	Ŧ
Receipts from customers (inclusive of GST)		6,586,715	4,066,491
Payments to suppliers (inclusive of GST)		(10,493,590)	(7,771,612)
R&D tax refund		327,739	223,275
Export Market Development Grant and State Government grants		43,600	46,530
Interest paid on lease liabilities		20,225	13,526
Interest received		18,406	852
Net cash used in operating activities	31	(3,496,905)	(3,420,938)
Cash flows from investing activities			
Payments for property, plant and equipment	13	(400,939)	(128,191)
Proceeds from disposal of property, plant and equipment			28,850
Net cash used in investing activities		(400,939)	(99,341)
Cash flows from financing activities			
Proceeds from issue of shares	22	500	9,678,651
Repayments for lease liabilities		(91,700)	(57,188)
Proceeds from borrowings		770,258	170,000
Share issue transaction costs		(13,844)	(1,137,351)
Repayment of borrowings		-	(250,417)
Net cash from financing activities		665,214	8,403,695
Net increase/(decrease) in cash and cash equivalents		(3,232,630)	4,883,416
Cash and cash equivalents at the beginning of the financial year		5,493,394	609,978
Cash and cash equivalents at the end of the financial year	9	2,260,764	5,493,394

Note 1. General information

The financial statements cover Biome Australia Limited as a consolidated entity consisting of Biome Australia Limited and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Biome Australia Limited's functional and presentation currency.

Biome Australia Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are:

Registered office

192-194 Johnston Street Collingwood Victoria 3066 Principal place of business 192-194 Johnston Street Collingwood Victoria 3066

Note 2. Significant accounting policies

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Basis of preparation

These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the Corporations Act 2001, as appropriate for for-profit oriented entities. These financial statements also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board ('IASB').

Historical cost convention

The financial statements have been prepared under the historical cost convention, except for, where applicable, the revaluation of financial assets and liabilities at fair value through profit or loss, financial assets at fair value through other comprehensive income, investment properties, certain classes of property, plant and equipment and derivative financial instruments.

Critical accounting estimates

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the consolidated entity's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3.

Parent entity information

In accordance with the Corporations Act 2001, these financial statements present the results of the consolidated entity only. Supplementary information about the parent entity is disclosed in note 29.

Principles of consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Biome Australia Limited ('company' or 'parent entity') as at 30 June 2023 and the results of all subsidiaries for the year then ended. Biome Australia Limited and its subsidiaries together are referred to in these financial statements as the 'consolidated entity'.

Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are de-consolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the consolidated entity are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the consolidated entity.

Note 3. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Note 4. Operating segments

Identification of reportable operating segments

The company is organised into one operating segment: researching, developing, manufacturing and distributing innovative evidence-based products linking the gut and human health. This operating segment is based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources. There is no aggregation of operating segments.

Note 5. Sales revenue

	Consolidated 30 June 2023 30 June 2 \$\$\$	2022
Sales - Domestic Sales - International Other Sales	6,775,876 3,819 459,735 293 - 9	
	7,235,611 4,122	,425

Note 6. Other income

	Consolidated 30 June 2023 30 June 2022	
	\$	\$
EMDG - Export Market Development Grant Victorian government grant Interest income R&D tax refund	36,600 7,000 18,406 <u>327,739</u>	43,530 3,000 852 223,275
Other income	389,745	270,657

Note 7. Expenses

		Consolidated 30 June 2023 30 June 2022		
	\$	\$		
Selling and marketing expenses				
Employee costs	2,030,136	1,790,153		
Sales & marketing expenses	1,533,202	1,261,163		
Travel expenses	322,971	178,108		
Distribution expenses	931,625	373,237		
Share based payments	112,564	-		
	4,930,498	3,602,661		

Note 7. Expenses (continued)

	Consoli 30 June 2023 3	
Corporate and administrative expenses		
Employee costs	1,534,815	1,235,072
Consulting fees	60,781	351,785
Accounting fees	106,285	104,599
IT expenses	292,986	310,902
Insurance	75,131	67,835
Secretarial fees	71,281	35,000
Legal fees	76,558	203,079
Other administrative expenses	2,110	16,810
Share based payments	25,000	467,564
	2,244,947	2,792,646
	Consoli	datad
	30 June 2023 3	
	50 Julie 2023 3	\$ Julie 2022
Dense sisting an entire tion and improved		
Depreciation, amortisation and impairments	100.000	06 400
Depreciation expense Depreciation expense on right-of-use asset	122,339 98,038	26,400 57,189
Depreciation expense on right-or-use asset	90,030	57,109
	220,377	83,589
	Consoli	dated
	30 June 2023 3	30 June 2022
Finance costs		
Interest expense	2,206	12,638
Interest expense on leases/right-of-use assets	20,224	13,526
Bank charges	3,584	2,672
Settlement discount	-	8,498
Merchant fees	5,271	3,369
Foreign exchange (gains)/losses	82,612	6,050
Bad debts		604
	113,897	47,357

Note 8. Income tax expense

	Consolidated 30 June 2023 30 June 202 \$\$\$	
Numerical reconciliation of income tax expense and tax at the statutory rate Loss before income tax expense	(3,078,527)	(4,540,580)
Tax at the statutory tax rate of 25%	(769,632)	(1,135,145)
Tax effect amounts which are not deductible/(taxable) in calculating taxable income: R&D refund R&D expenses Share-based payments Timing differences not recognised	(81,935) 187,500 34,391 135,410 (494,266) 494,266	(55,819) 103,448 116,891 189,256 (781,369) 781,369
Income tax expense		
	Consoli 30 June 2023 3 \$	
<i>Tax losses not recognised</i> Unused tax losses for which no deferred tax asset has been recognised	11,416,558	9,439,495
Potential tax benefit @ 25%	2,854,140	2,359,874

The above potential tax benefit for tax losses has not been recognised in the statement of financial position. These tax losses can only be utilised in the future if the continuity of ownership test is passed, or failing that, the same business test is passed and the Group generates sufficient taxable earnings.

Note 9. Current assets - cash and cash equivalents

	Consolic 30 June 2023 3 \$	
Cash at bank	2,260,764	5,493,394
Note 10. Current assets - trade and other receivables		
	Consolidated 30 June 2023 30 June 2022 \$ \$	
	30 June 2023 3	0 June 2022
Trade receivables Other receivables	30 June 2023 3	0 June 2022

8

Note 11. Current assets - inventories

	Consolio 30 June 2023 3	
	\$	\$
Raw materials - at cost	253,170	-
Finished goods - at cost	2,971,489	1,555,941
Provision for slow moving and obsolete stock	(203,345)	(255,866)
	3,021,314	1,300,075

Note 12. Current assets - other

	Consolida 30 June 2023 30 \$	
Other	15,652	1,055
Bank deposit	30,250	54,884
	45,902	55,939

Note 13. Non-current assets - property, plant and equipment

	Consolid 30 June 2023 30 \$	
Property, plant and equipment - at cost Less: Accumulated depreciation	631,509 (178,214)	230,569 (55,874)
	453,295	174,695

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

	Furniture, Fixtures and Fittings	Motor Vehicles	Leasehold Improvement	Office Equipment	
Consolidated	\$	\$	\$	\$	Total \$
Balance at 1 July 2021	-	105,593	-	-	105,593
Additions	-	-	128,191	-	128,191
Disposals	-	(32,689)	-	-	(32,689)
Depreciation expense	<u> </u>	(26,400)			(26,400)
Balance at 30 June 2022	-	46,504	128,191	-	174,695
Additions	21,770	-	345,633	33,536	400,939
Depreciation expense	(937)	(26,400)	(92,906)	(2,096)	(122,339)
Balance at 30 June 2023	20,833	20,104	380,918	31,440	453,295

Note 14. Non-current assets - right-of-use assets

	Consolidat 30 June 2023 30 J \$	
Right-of-use assets Accumulated depreciation	490,189 (155,226)	490,189 (57,189)
	334,963	433,000

Note 15. Current liabilities - trade and other payables

	Consolidated 30 June 2023 30 June 2022 \$ \$	
Trade and other payables	2,274,371 1,125,558	
Refer to note 26 for further information on financial instruments.		
Note 16. Current liabilities - borrowings		

Con 30 June 20 \$		
Loans - other (refer note 28 related party transactions)	125,018	

Refer to note 26 for further information on financial instruments.

Lease liabilities

The maturity analysis of lease liabilities based on contractual undiscounted cash flows is shown in the table below:

	< 1 year \$	1 - 5 years \$	> 5 years \$	Total undiscounted lease liabilities \$	Lease liabilities included in this Statement Of Financial Position \$
2023 Lease liabilities	115,283	292,630	-	407,913	375,349
2022 Lease liabilities	111,925	407,913	-	519,838	467,048

The amounts recognised in the statement of profit or loss and other comprehensive income relating to interest expense on lease liabilities and short-term leases or leases of low value assets are shown below:

	2023	2022
	\$	\$
Interest expense on lease liabilities	20,224	13,526
Depreciation expense	98,038	57,189
	118,262	70,715

Note 17. Current liabilities - lease liabilities

	Consolidated 30 June 2023 30 June 2022 \$\$\$
Lease liability	99,584 91,700
Note 18. Current liabilities - employee benefits	
	Consolidated 30 June 2023 30 June 2022 \$ \$

	300,000
133,598	487,413

187,413

133,598

Note 19. Non-current liabilities - borrowings

Annual leave

Employee benefits

	Consolidated 30 June 2023 30 June 2022	
	\$	\$
Business loan (refer note 28 related party transactions)	145,240	-
Trade finance facility (refer to note 29 re. guarantees entered into by the parent entity)	500,000	-
	645,240	

Note 20. Non-current liabilities - lease liabilities

	Consolidated 30 June 2023 30 June 2022	
	\$	\$
Lease liability	275,765	375,348

Note 21. Non-current liabilities - employee benefits

	Consolidated 30 June 2023 30 June 2022 \$ \$	
Long service leave	65,626 -	
Note 22. Equity - issued capital		
	Consolidated 30 June 2023 30 June 2022 30 June 2023 30 June 2022 Shares Shares \$ \$	
Ordinary shares - fully paid	201,812,546 199,909,857 20,764,055 20,639,835	

Note 22. Equity - issued capital (continued)

Movements in ordinary share capital

Details	Date	Shares	Issue price	\$
Balance Issue of shares	1 July 2021 19 July 2021 - 31	301,464,273		9,830,488
	August 2021	27,976,494	\$0.06	1,678,651
Exercise of performance rights	3 & 18 August 2021	12,647,708	\$0.06	758,862
Consolidation of capital on a 2.3 : 1 basis	18 October 2021	(193,354,525)	-	-
Issue of shares through initial public offering	24 November 2021	40,000,000	\$0.20	8,000,000
Conversion of performance rights	24 November 2021	11,175,907	\$0.13	1,542,275
Capital raising costs				(1,170,441)
Balance	30 June 2022	199,909,857		20,639,835
Employee incentive plan	18 January 2023	1,902,689	\$0.0723	137,564
Issue of unlisted options	31 March 2023	-	-	500
Capital raising costs			-	(13,844)
Balance	30 June 2023	201,812,546	-	20,764,055

Ordinary shares

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back

There is no current on-market share buy-back.

Capital risk management

The consolidated entity's objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents.

In order to maintain or adjust the capital structure, the consolidated entity may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

The consolidated entity would look to raise capital when an opportunity to invest in a business or company was seen as value adding relative to the current company's share price at the time of the investment. The consolidated entity is not actively pursuing additional investments in the short term as it continues to integrate and grow its existing businesses in order to maximise synergies.

The consolidated entity is subject to certain financing arrangements covenants and meeting these is given priority in all capital risk management decisions. There have been no events of default on the financing arrangements during the financial year.

Note 23. Equity - reserves

	Consolid 30 June 2023 30 \$	
Share option and performance rights reserves	421,257	415,442
Note 24. Equity - accumulated losses		

	Consoli 30 June 2023 3 \$	
Accumulated losses at the beginning of the financial year Loss after income tax expense for the year Cancellation of options Transfer from reserves	(14,530,230) (3,078,527) 9,710	(9,893,535) (4,540,580) 59,437 (155,552)
Accumulated losses at the end of the financial year	(17,599,047)	(14,530,230)

Note 25. Equity - dividends

There were no dividends paid, recommended or declared during the current or previous financial year.

Note 26. Financial instruments

Financial risk management objectives

The consolidated entity's principal financial instruments comprise cash, short term deposits and equity investments. The main purpose of the cash and term deposit is to earn the maximum amount of interest at a low risk to the consolidated entity. The consolidated entity also has other financial instruments such as trade debtors and creditors which arise directly from its operations. For the period under review, it has been the consolidated entity's policy not to trade in financial instruments.

The directors' overall risk management strategy seeks to assist the consolidated entity in meeting its financial targets, whilst minimising potential adverse effects on financial performance.

Risk management is carried out by senior finance executives ('finance') under policies approved by the Board of Directors ('the Board'). These policies include identification and analysis of the risk exposure of the consolidated entity and appropriate procedures, controls and risk limits. Finance identifies, evaluates and hedges financial risks within the consolidated entity's operating units. Finance reports to the Board on a monthly basis.

Market risk

Foreign currency risk

The consolidated entity undertakes certain transactions denominated in foreign currency and is exposed to foreign currency risk through foreign exchange rate fluctuations.

Foreign exchange risk arises from future commercial transactions and recognised financial assets and financial liabilities denominated in a currency that is not the entity's functional currency. The risk is measured using sensitivity analysis and cash flow forecasting.

Price risk

The consolidated entity is not exposed to any significant price risk.

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate due to changes in market interest rates. Current financial assets and financial liabilities are generally not exposed to interest rate risk because of their short-term nature. At 30 June 2023, the consolidated entity's cash/cash equivalents (note 9) are variable interest rate instruments earning approximately 3.80% p.a. at call interest.

Note 26. Financial instruments (continued)

Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the consolidated entity. The consolidated entity has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral where appropriate, as a means of mitigating the risk of financial loss from defaults. The consolidated entity only transacts with entities that are rated the equivalent of investment grade and above. The consolidated entity's exposure and the credit ratings of its counterparties are continuously monitored. Credit exposure is controlled by counterparty limits that are reviewed and approved by the Board annually. The consolidated entity does not have any borrowings and therefore does not have any associated credit risk.

Generally, trade receivables are written off when there is no reasonable expectation of recovery. Indicators of this include the failure of a debtor to engage in a repayment plan, no active enforcement activity and a failure to make contractual payments for a period greater than 1 year.

Liquidity risk

Vigilant liquidity risk management requires the consolidated entity to maintain sufficient liquid assets (mainly cash and cash equivalents) and available borrowing facilities to be able to pay debts as and when they become due and payable.

The consolidated entity manages liquidity risk by maintaining adequate cash reserves and available borrowing facilities by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities.

Fair value of financial instruments

Unless otherwise stated, the carrying amounts of financial instruments reflect their fair value.

Note 27. Remuneration of auditors

During the financial year the following fees were paid or payable for services provided by JTP Assurance, the auditor of the company:

		Consolidated 30 June 2023 30 June 2022	
	\$	\$	
Audit services - JTP Assurance Audit or review of the financial statements	36.00	0 32.000	
Addit of Tevlew of the infancial statements	30,00	0 52,000	

Note 28. Related party transactions

Parent entity Biome Australia Limited is the parent entity.

Transactions with related parties

The CFO provided a personal guarantee on a 3-year American Express Business Loan with an outstanding loan balance of \$145,240 as at 30 June 2023 (2022: Nil).

Loans to/from related parties

There was an outstanding interest free loan owing to the CFO of \$125,018 as at 30 June 2023 (2022: Nil).

Note 29. Parent entity information

Set out below is the supplementary information about the parent entity.

Statement of profit or loss and other comprehensive income

	Pare 30 June 2023 \$	
Loss after income tax	(297,724)	(1,313,668)
Total comprehensive income	(297,724)	(1,313,668)
Statement of financial position		
	Parc 30 June 2023 \$	
Total current assets	1,066,820	3,619,279
Total assets	16,901,618	17,069,307
Total current liabilities		
Total liabilities	<u>-</u>	
Equity Issued capital Share option and performance rights reserves Accumulated losses	20,764,055 421,257 (4,283,694)	20,639,835 415,442 (3,985,970)
Total equity	16,901,618	17,069,307

Guarantees entered into by the parent entity in relation to the debts of its subsidiaries

The parent entity has entered into a Deed of Guarantee and Indemnity in relation to a \$1.2 million (2022: \$Nil) secured debt facility of its wholly owned subsidiary, Biome Australia Trading Pty Ltd with AMAL Trustees Pty Ltd as at 2023.

Interest in subsidiaries

	Principal place of business / Country of Incorporation	Percentage Owned 2023 %	Percentage Owned 2022 %
Subsidiaries: Biome Australia Trading Pty Ltd Biome Australia IP Pty Ltd	Melbourne, Victoria, Australia Melbourne, Victoria, Australia	100% 100%	100% 100%

Contingent liabilities

As outlined in Section 6.7.1 of the Prospectus dated 19 October 2021 the Managing Director is entitled to a long term incentive (LTI) should specified consolidated revenue targets be delivered over a three year period. The maximum liability under this plan is \$1,000,000 to be earned over a three-year period up to and including the year ending 30 June 2024. The Company intends to start accruing this liability in its accounts once the minimum 80% LTI target of \$16.8m cumulative sales is met prior to 30 June 2024.

The parent entity has no other known contingent liabilities as at 2022 and 2023.

Note 29. Parent entity information (continued)

Capital commitments - Property, plant and equipment The parent entity had no capital commitments at 2022 and 2023.

Significant accounting policies

The accounting policies of the parent entity are consistent with those of the consolidated entity, as disclosed in note 2, except for the following:

- Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity.
- Investments in associates are accounted for at cost, less any impairment, in the parent entity.
- Dividends received from subsidiaries are recognised as other income by the parent entity and its receipt may be an indicator of an impairment of the investment.

Note 30. Events after the reporting period

No matter or circumstance has arisen since 30 June 2023 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Note 31. Reconciliation of loss after income tax to net cash used in operating activities

	Consolidated 30 June	
	30 June 2023 \$	2022 \$
Loss after income tax expense for the year	(3,078,527)	(4,540,580)
Adjustments for:		
Depreciation and amortisation	220,377	83,588
Share-based payments	153,089	467,564
Interest on lease payments	20,224	13,526
Adjustment for IPO costs	-	543,297
Change in operating assets and liabilities:		
Increase in trade and other receivables	(648,896)	(55,325)
Increase in inventories	(1,721,239)	(148,517)
Decrease/(increase) in prepayments	10,037	(31,305)
Decrease in other operating assets	-	297,295
Increase/(decrease) in trade and other payables	1,128,589	(50,481)
Increase in employee benefits	419,441	-
Net cash used in operating activities	(3,496,905)	(3,420,938)

Note 32. Earnings per share

	Consol 30 June 2023 \$	
Loss after income tax attributable to the owners of Biome Australia Limited	(3,078,527)	(4,540,580)
	Number	Number
Weighted average number of ordinary shares used in calculating basic earnings per share	200,764,764	176,495,071
Weighted average number of ordinary shares used in calculating diluted earnings per share	200,764,764	176,495,071
	Cents	Cents
Basic earnings per share Diluted earnings per share	(1.53) (1.53)	(2.57) (2.57)

Note 33. Share-based payments

Set out below are summaries of shares issued under the Company's Employee Incentive Plan:

30 June 2023			No. of Coourity	
Issue Date	Security Issued	Issue Price	No of Security Issued	Value of Security Issued
18/01/2023	Fully paid shares	\$0.0723	1,902,689	\$137,564

Set out below are summaries of options granted for services rendered:

30 June 2023

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
31/03/2023 31/03/2023	31/03/2026 31/03/2026	\$0.12 \$0.20		2,500,000 2,500,000 5,000,000		-	2,500,000 2,500,000 5,000,000

Share options granted carry no rights to dividends and no voting rights. The options fully vested on issue. Valuation of the options has been undertaken using an industry standard pricing model. Refer below for further information.

Grant date	Expiry date	Share price at grant date	Exercise price	Expected volatility	Dividend yield	Risk-free interest rate	Fair value at grant date
31/03/2023 31/03/2023	31/03/2026 31/03/2026	\$0.07 \$0.07	\$0.12 \$0.20	31.65% 31.65%	-	2.93% 2.93%	\$13,350.00 \$2,175.00
30 June 2022 Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
24/11/2021 24/11/2021	24/11/2024 24/11/2025	\$0.30 \$0.40	-	2,131,404 2,131,404 4,262,808	-	- - -	2,131,404 2,131,404 4,262,808

Note 34. Commitments and Contingencies

(a) Capital expenditure commitments

The group has no (2022: \$260,000) capital commitments as at 30 June 2023.

(b) Contingent liabilities

As outlined in Section 6.7.1 of the Prospectus dated 19 October 2021 the Managing Director is entitled to a long term incentive (LTI) should specified consolidated revenue targets be delivered over a three year period. The maximum liability under this plan is \$1,000,000 to be earned over a three-year period up to and including the year ending 30 June 2024. The Company intends to start accruing this liability in its accounts once the minimum 80% LTI target of \$16.8m cumulative sales is met prior to 30 June 2024.

The group has no other known contingent liabilities at 2022 and 2023